Mizuho Lowers Price Target for ADMA Biologics Inc. to $24

Mizuho Financial Group has lowered its price target for ADMA Biologics Inc. (NASDAQ:ADMA) from $30 to $24, maintaining an Outperform rating. The move comes amid concerns over the company's financial practices and investor sentiment following a short report. ADMA's stock has dropped 14.7% week-over-week as three executives sold shares.

By Noor Ul Ain Rehman Mon, April 20, 2026 at 3:12 AM GMT+3 2 min read · Yahoo Finance · April 20, 2026, 00:12 UTC

Tickers: $ADMA

Topics: ADMA Biologics analyst downgrade biotech price target stock rating

Read the full article at Yahoo Finance

More World news

The Adecco Group Reports Q3 2026 Growth Driven by Temporary Staffing and Margin Expansion PR Newswire · November 12, 2026, 18:54 UTC
Twist Bioscience Projects FY2027 Revenue Between $550M and $560M Seeking Alpha · November 12, 2026, 18:50 UTC
Dixie Group Reports Q3 Sales Growth Amid Margin Pressure and Future Cost-Reduction Targets Seeking Alpha · November 12, 2026, 18:50 UTC
Data I/O Corporation Targets Rapid V-TEK Synergy Realization Amid $80 Million M&A Pipeline Seeking Alpha · November 12, 2026, 18:50 UTC
Leatt Corporation Reports 43% Increase in Q3 Revenue to $20.46 Million Seeking Alpha · November 12, 2026, 18:50 UTC
Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC
C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion Motley Fool · November 12, 2026, 18:45 UTC
Baker Hughes Raises Guidance Amid Surging Data Center Power Demand Motley Fool · November 12, 2026, 18:45 UTC
California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC
Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class PR Newswire · November 12, 2026, 18:41 UTC